Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Why this Year’s Flu Vaccine May Make You Sicker
  • USA - English


News provided by

The Mountains Voice

Dec 11, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


“This Phenomenon could pose a cause for concern in the context of human immune responses to influenza vaccination programs.” – Medical Study Posted at National Center for Biotechnology Information Website

Post this

Big Canoe, GA (PRWEB) December 11, 2014 -- The CDC says that this year’s Influenza vaccine does not match the primary H3N2 flu strain which is circulating, yet they continue to promote getting the vaccine this season - even though 50 years of research indicates a potentially deadly outcome for those that do receive this particular vaccine. At issue is a well-studied phenomenon known as “Original Antigenic Sin.” This in-depth original research article, released by startup online news outlet TheMountainsVoice.net, is compiled using research data from a dozen documented reference sources all identified in the full article.

On December 4th 2014, the CDC issued a Press Release [1, 2] stating that the current Flu Vaccine was not going to be a good match for the H3N2 flu strains which will be circulating this winter; that the virus had “drifted” --- (Layman’s Term: mutated or changed) --- away from the antibody formulation used in the vaccine. Yet the CDC is “still strongly recommending vaccination” claiming that “vaccination has been found to provide some protection against drifted viruses in past seasons.”

The limited protection that the mismatched vaccine would provide is referred to as cross-reactivity. However, to insinuate that vaccination will produce the benefits of cross-reactivity is a very misleading claim, and only tells one side of the story. The other side of the story involves something commonly referred to since the 1950’s as the “Doctrine of Original Antigenic Sin” [3 - 6]. This well established research subject helps to explain how “original antigenic sin could make vaccinated people more susceptible to the virus than those who are unvaccinated [7].“

CROSS-REACTIVITY vs. ORIGINAL ANTIGENIC SIN

Normally when someone is vaccinated for an existing flu strain – let’s call it Flu-1 - they develop Flu-1 antibodies. If Flu-1 “drifts” (mutates) far enough to create a new flu – let’s call it Flu-2 - then the Flu-1 antibodies are NOT a good match to the Flu-2 virus, and subsequently the Flu-1 vaccine created antibodies won’t work against the new Flu-2 virus, unless cross-reactivity is exhibited. Cross-Reactivity is a term which indicates the Flu-1 antibodies may still provide some limited protection against Flu-2 virus. So cross-reactivity is considered an “OK” thing, because some protection (even if minimal) is better than none.

Original Antigenic Sin (OAS) is completely different, and if triggered in the above scenario would result in a bad outcome. According to a 2012 research article released by Emory University, OAS “can impair immune responses to new flu strains [8].“ Imagine the scenario above in which a person gets a Flu-1 vaccine, develops Flu-1 antibodies, and then later catches the Flu-2, which has changed enough that the vaccine doesn’t even provide partial protection. OAS involves this scenario taking place PLUS one additional negative factor: The body still has a false “immune memory” of the Flu-1 antibodies, and it thinks that the Flu-1 antibodies will still work against Flu-2 virus [9]. So when the body detects the Flu-2 infection, it launches the wrong response - putting all of its energy into creating the WRONG Flu-1 antibodies, and all the while the Flu-2 virus is multiplying and establishing itself in the body with a very high viral load.

IF OAS is triggered by a vaccine that doesn’t match the strain of flu circulating (as is the case this year) – then the vaccine recipients are potentially in much worse condition than if they had never received the vaccine in the first place. If the vaccine recipient is also in a high risk category, then their chances of having major complications, being hospitalized, or dying increase.

Read the entire story, with full supporting research references, at our main news site:
http://themountainsvoice.net/why-this-years-flu-vaccine-may-make-you-sicker-p262-161.htm

REFERENCES:

1. CDC Press Release: Early Data Suggests Potentially Severe Flu Season - Thursday, Dec 4, 2014
http://www.cdc.gov/media/releases/2014/p1204-flu-season.html
2. CDC Media Briefing associated with Press Release on Thursday, December 4, 2014
Transcript: http://www.cdc.gov/media/releases/2014/t1204-flu-season.html
Audio: http://www.cdc.gov/media/releases/2014/t1204-flu-season.mp3
3. Francis T. 1955. The current status of the control of influenza. Ann. Intern. Med. 43:534–538. http://dx.doi.org/10.7326/0003-4819-43-3-534.
4. Davenport. F. M. and Hennessy, A. V. (1956) Serologic recapitulation of past experiences with influenza A: antibody response to monovalent vaccine. J. Exp. Med. 104. 85—97.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2136633/pdf/85.pdf
5. Francis T. 1960. On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 104:572–578.
6. Disquisitions on Original Antigenic Sin: I. Evidence in Man; SFS Groth, RG Webster - The Journal of Experimental Medicine, 1966. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2138235/pdf/331.pdf
7. Original sin and the risk of epidemics. University of Cambridge Research; published 10 Oct 2012
http://www.cam.ac.uk/research/news/original-sin-and-the-risk-of-epidemics
8. Flu vaccine research: Overcoming 'original sin' – Emory University; published August 17, 2012
http://www.sciencedaily.com/releases/2012/08/120817092509.htm
9. Pan K (2011) Understanding Original Antigenic Sin in Influenza with a Dynamical System. PLoS ONE 6(8): e23910. doi:10.1371/journal.pone.0023910
http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0023910&representation=PDF

ABOUT THE AUTHOR: david is an independent writer/researcher and publisher. He began researching infectious diseases (primarily influenza) in 2001, and was at the time one of the first bloggers to identify H5N1 as a potential future pandemic source. After over a decade of random forum and blog posts, david has launched an online regional news outlet in the North Georgia Mountains with a regional focus on political, real estate and banking investigations, along with general research and editorial pieces directed at national & global topics. This is the 1st story to be released on his new fixed online news site.

david hopkins, The Mountains Voice, http://www.TheMountainsVoice.net, +1 678-327-3127, [email protected]

Modal title

FULL ARTICLE: Why This Years Vaccine May Make You Sicker
View PDF
FULL ARTICLE: Why This Years Vaccine May Make You Sicker
FULL ARTICLE: Why This Years Vaccine May Make You Sicker

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.